{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:07:18Z","timestamp":1790255238077,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AU-0042-20030616"],"award-info":[{"award-number":["AU-0042-20030616"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP190561"],"award-info":[{"award-number":["RP190561"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP250465"],"award-info":[{"award-number":["RP250465"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201319","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:57:47Z","timestamp":1787259467000},"page":"201319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-164X","authenticated-orcid":false,"given":"Junquan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4348-2180","authenticated-orcid":false,"given":"Ningyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-9115","authenticated-orcid":false,"given":"Andras","family":"Heczey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201319_bib1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2026.201319_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2326-6066.CIR-25-0609","article-title":"Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells","volume":"14","author":"Cunningham","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201319_bib3","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/0008-5472.CAN-20-1418","article-title":"ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen","volume":"80","author":"Su","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201319_bib4","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.celrep.2020.02.090","article-title":"Identification of ALPPL2 as a Na\u00efve Pluripotent State-Specific Surface Protein Essential for Human Na\u00efve Pluripotency Regulation","volume":"30","author":"Bi","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201319_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/nat.2014.0516","article-title":"ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2'-Deoxyuridine to Pancreatic Cancer","volume":"25","author":"Dua","year":"2015","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omton.2026.201319_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151761","article-title":"Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance antitumor immunity","volume":"762","author":"Xu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omton.2026.201319_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201319_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201319_bib9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:40:53Z","timestamp":1790253653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001955"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201319","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201319"}}